MedPath

AI Screening for Diabetic Retinopathy

Recruiting
Conditions
Diabetes Mellitus
Interventions
Diagnostic Test: artificial intelligence (AI) algorithm of the MONA DR model
Registration Number
NCT05704491
Lead Sponsor
West German Center of Diabetes and Health
Brief Summary

The increasing prevalence of diabetes mellitus represents a major health problem, especially since around 40% of diabetic patients develop diabetic retinopathy, which severely impairs vision and can lead to blindness. This development could be prevented by annual check-ups and timely referral for treatment. However, there are major differences in the quality of examinations and bottlenecks in examination appointments. A solution to the problem could be the use of artificial intelligence (AI), especially deep learning. Initial studies have shown that deep learning algorithms can be used successfully to detect diabetic retinopathy. However, it remains to be clarified whether the use of AI can achieve a sufficiently high level of accuracy in the detection of retinopathies. Therefore, in the present study, the positive predictive value (PPV), the negative predictive value (NPV), the sensitivity (SEN) and the specificity (SPEZ) of the AI algorithm 'MONA-DR-Model' in the detection of diabetic retinopathy should be measured. In addition, it is to be examined how well the classification into mild and severe retinopathy corresponds and how well this new examination method is accepted by the patients.

Detailed Description

As part of the study, a 45-degree fundus image is taken for each eye and patient using the 'Crystalvue NFC 600'. The fundus photographs are then analyzed using the 'MONA-DR-Mode'l and classified as "diabetic retinopathy according to AI present (K+)" or "diabetic retinopathy according to AI absent (K-)". These classifications are compared with the results ("diabetic retinopathy according to the doctor present (A+)" or "diabetic retinopathy according to the doctor absent (A-)") of the examinations routinely provided for in the Disease Management Program (DMP) diabetes mellitus type 2 by resident ophthalmologists who work in the period 6 months before and after the fundus photography in the West German Centre of Diabetes and Health (WDGZ) were compared. All patients with the assessment "diabetic retinopathy according to AI present (K+)" or discrepancies with the ophthalmological DMP examination in the outpatient environment are offered a routine appointment at the Marienhospital. There, an eye examination is then carried out by an ophthalmologist and, without knowledge of the previous findings, a reassessment and classification as "diabetic retinopathy according to the doctor present (A+)" or "diabetic retinopathy according to the doctor absent (A-)" is carried out by the AI.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Diagnosis of diabetes mellitus
  • Diabetes duration ≥ 5 years
  • Age > 18 years old
  • Patient is able to give informed consent
  • Fluent in written and spoken German, or interpreter present
Exclusion Criteria
  • History of laser treatment
  • Contraindication to the fundus imaging systems used in the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
K+A+artificial intelligence (AI) algorithm of the MONA DR modeldiabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor present (A+)
K-A+artificial intelligence (AI) algorithm of the MONA DR modeldiabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor present (A+)
K+A-artificial intelligence (AI) algorithm of the MONA DR modeldiabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor absent (A-)
K-A-artificial intelligence (AI) algorithm of the MONA DR modeldiabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor absent (A-)
Primary Outcome Measures
NameTimeMethod
SEN12 months

sensitivity

NPV12 months

negative predictive value

SPEZ12 months

specificity

PPV12 months

positive predictive value

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

West German Center of Diabetes and Health

🇩🇪

Düsseldorf, Germany

© Copyright 2025. All Rights Reserved by MedPath